PDF
ePub
Citation
Print
Abstract
Background:
To investigate the efficacy and adverse effects of a single dose of anti-D immunoglobulin (50μg/kg) in Korean children with acute immune thrombocytopenic purpura (ITP).
Methods:
We serially evaluated the platelet count in 21 acute ITP patients that were treated with anti-D immunoglobulin (50μg/kg) to determine how many patients achieved platelet counts over the levels of 20×103/mm3, 50×103/mm3 and 100×103/mm3 after the infusion of anti-D immunoglobulin. In addition, constitutional symptoms were monitored and changes in the hemoglobin levels were serially evaluated.
Results:
By three days after treatment, 90.5% of the patients had achieved a platelet count over 20× 103/mm3. At seven days after treatment, 66.7% of patients achieved a platelet count of 50×103/mm3. In addition, at seven days after treatment 61.9% of patients achieved a platelet count of 100×103/mm3. Constitutional adverse symptoms were observed 61.9% of patients, and the symptoms diminished spontaneously without any severe sequelaes. The decline of hemoglobin concentration after treatment recovered to the initial level after two weeks.
REFERENCES
1). Kuhne T. Idiopathic thrombocytopenic purpura of childhood: a problem-oriented review of the management. Transfus Apher Sci. 2003. 28:243–8.
2). Kuhne T., Imbach P., Bolton-Maggs PH., Berchtold W., Blanchette V., Buchanan GR. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001. 358:2122–5.
3). George JN., Woolf SH., Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996. 88:3–40.
4). Medeiros D., Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998. 133:334–9.
5). Blanchette V., Imbach P., Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994. 344:703–7.
6). Tarantino MD., Madden RM., Fennewald DL., Patel CC., Bertolone SJ. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr. 1999. 134:21–6.
7). Tarantino MD., Young G., Bertolone SJ, et al. Single dose of anti-D immune globulin at 75μg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006. 148:489–94.
8). Park HY, Kang CG, Shin MY, Ahn KM, Sung KW, Koo HH, Treatment of childhood idiopathic thrombocytopenic purpura with anti-D (WinRhoⓇ). Korean J Pediatr Hematol-Oncol. 2000. 7:187–93.
9). Hong F., Ruiz R., Price H., Griffiths A., Malinoski F., Woloski M. Safety profile of WinRho anti-D. Semin Hematol. 1998. 35:9–13.
10). Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005. 106:1532–7.
11). Christopher K., Horkan C., Barb IT., Arbelaez C., Hodgdon TA., Yodice PC. Rapid irreversible encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura. Am J Hematol. 2004. 77:299–302.
12). Chun NS., Savani B., Seder RH., Taplin ME. Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. Am J Hematol. 2003. 74:276–9.
13). Taube T., Schmid H., Reinhard H., von Stackelberg A., Overberg US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005. 90:281–3.
14). Wang J., Wiley JM., Luddy R., Greenberg J., Feu-erstein MA., Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005. 146:217–21.
15). Jenkins JM., Williams D., Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007. 109:4739–41.
16). Bussel JB., Kuter DJ., George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006. 355:1672–81.
17). Wang B., Nichol JL., Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004. 76:628–38.
18). Ware RE., Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol. 1998. 35:14–22.
19). Imbach P., Barandun S., d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981. 1:1228–31.
Fig. 1
Rate of platelet response over 20×103/mm3 per time in patients treated with anti-D. Values in whole bar (□ ■) and black portion (■) indicate the total subjects and the subjects who showed platelet count over 20× 103/mm3, respectively.
Fig. 2
Rate of platelet response over 50×103/mm3 per time in patients treated with anti-D. Values in whole bar (□ ■) and black portion (■) indicate the total subjects and the subjects who showed platelet count over 50× 103/mm3, respectively.
XML Download